PositoAI/ JP/ Astellas Pharma Inc.

Astellas Pharma Inc.

Tokyo: 4503 · Healthcare

Positivity Index

#5,634 / 8,498

Global

#1,280 / 1,440

Japan

Positivity Score

19,899

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Astellas Pharma Inc. — Overview & Financial Snapshot

Astellas Pharma Inc. (Tokyo: 4503) is a Healthcare company, ranked #5,634 of 8,498 companies globally and #1,280 of 1,440 in Japan on PositoAI, with a Positivity Score of 19,899. Its market capitalisation is ₹2.73 lakh Cr (¥4.51T), P/E ratio is 12.2 and P/B ratio is 2.32. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#30 Seikagaku Corporation 23,988 #37 EM Systems Co., Ltd. 23,902 #39 Amvis Holdings, Inc. 23,875 #46 KYORIN Pharmaceutical Co., Ltd. 23,796 #52 Tsuruha Holdings Inc. 23,710

— Nothing to show —

OpenAI is reading recent news...

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

P/B Ratio 2.32

P/E Ratio 12.2

D/E Ratio 0.30

ROE 21.30%

Owes vs Owns ? —Not available

Dividend Yield 3.18%

Trailing EPS ₹125.21¥206.83

Forward EPS ₹45.87¥75.77

Beta 0.09

Market Cap ₹2.73 lakh Cr¥4.51T

What these numbers mean →

What does Astellas Pharma Inc. do?

What is Astellas Pharma Inc.'s P/E and P/B ratio?

Astellas Pharma Inc. has a P/E ratio of 12.2 and a P/B ratio of 2.32.

What is Astellas Pharma Inc.'s debt-to-equity ratio?

Astellas Pharma Inc. has a debt-to-equity ratio of 0.30.

What is Astellas Pharma Inc.'s Positivity rank?

Astellas Pharma Inc. is ranked #5,634 of 8,498 companies globally and #1,280 of 1,440 in Japan on PositoAI, with a Positivity Score of 19,899.

Does Astellas Pharma Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Astellas Pharma Inc..

Where can I read the latest news about Astellas Pharma Inc.?

Recent headlines about Astellas Pharma Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Astellas Pharma Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Astellas Pharma Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.